Actively Recruiting
Evaluating Maridebart Cafraglutide for Adults with Obesity or Overweight Switching from GLP-1 Receptor Agonists A Phase 3 Open-label Randomized Trial
Led by Amgen · Updated on 2026-10-23
300
Participants Needed
54
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
This trial evaluates the efficacy, safety, and tolerability of switching from glucagon-like peptide-1 receptor agonists GLP-1RA to maridebart cafraglutide in adults with obesity or overweight. It aims to assess how maridebart cafraglutide affects body weight and other safety measures in this population. The study is a Phase 3, open-label, randomized trial sponsored by Amgen. Participants are randomly assigned to one of two dosing schedules of maridebart cafraglutide, which is administered via subcutaneous injection. The treatment period involves receiving one of these dosing regimens to compare their effects. The study focuses on switching from prior weekly GLP-1RA treatment to maridebart cafraglutide and monitors participants throughout the treatment. During the trial, participants will have their body weight measured at baseline and at Week 68 to determine the percentage change. Additional assessments include plasma concentration of maridebart cafraglutide and monitoring for treatment-emergent adverse events up to 84 weeks. Participants are expected to maintain stable body weight and gastrointestinal tolerability before and during the trial, with contraception required for females. Overall, the study duration extends through the treatment period and safety follow-up.
CONDITIONS
Brief Title
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Research Team
A
Amgen Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here